Presentation Q3 Report 2021 “Strong order growth and our

Presentation Q3 Report 2021

“Strong order growth and our remediation measures completed in Germany”

Mattias Perjos, President & CEO

Lars Sandström, CFO

October 20, 2021

• Strong organic order growth

• Net sales down vs record Q3 2020

• Adj EBITA margin 18.4%

• Strong Free Cash Flow

• Solid financial position

Q3 2021

Key takeaways – a strong quarter from a financial perspective

October 20, 2021

52

Q2 2

019

Q1 2

019

Q4 2

020

Q3 2

019

Q1 2

021

Q4 2

019

Q1 2

020

Q2 2

020

Q3 2

020

Q2 2

021

53.0

Q3 2

021 0

15

Q4 2

020

Q1 2

019

Q2 2

019

Q3 2

019

Q4 2

019

Q1 2

020

Q2 2

020

Q3 2

021

Q3 2

020

Q1 2

021

Q2 2

021

19.0

Getinge │ Presentation │ Q3 Report 2021

Page 2

R12 Gross Margin (adj) % R12 EBITA Margin (adj) %

25,000

0

Q2 2

019

Q1 2

019

Q3 2

019

Q4 2

019

Q1 2

020

Q2 2

020

Q3 2

020

Q4 2

020

Q1 2

021

Q2 2

021

27,901Q

3 2

021

R12M Net Sales, MSEK

Strengthening the offering further

• Launch of Rotaflow II for ECMO-therapy

• Launch of the unique Volista VisioNIR-

functionality for surgical light

• Acquisition of advanced technology

for biological indicators from Verrix

The improvement journey continues

• Remediation measures completed in Germany

• Capacity increase in Life Science is progressing

according to plan

October 20, 2021


Page 3

Key activities and eventsQ3 2021

In all Business Areas and regions

Strong organic order growth in Q3

Americas EMEA APAC

Organic Order Growth

+21.8%

Organic Net Sales Growth

-20.1%

Global

October 20, 2021


Page 4

October 20, 2021


Page 5

Outlook 2021

Net sales is expected to be at least 27 BSEK

Strong organic order growth in all Business AreasOrder Intake – Bridge Q3 2020 – Q3 2021

545204

432

Q3 2020

5,898

Life ScienceAcute Care

Therapies

Surgical

Workflows

7,079

Q3 2021

MS

EK

+18.6% +29.6% +24.6%Organic change +21.8%

October 20, 2021


Page 6

6,678

Q3 2019

Life Science grows net sales by 17.5% organicallyNet Sales – Bridge Q3 2020 – Q3 2021

120

Acute Care

Therapies

-73

Life Science

7,976

Q3 2020

-1,718

6,306

Surgical

Workflows

Q3 2021

MS

EK

-31.6% +17.5% -2.9%Organic change -20.1%

October 20, 2021


Page 7

6,236

Q3 2019 -41.2

ConsumablesCapital

Goods

Org

anic

gro

wth

, %

7.8

-77Currency impact, MSEK

Margin improvement in Life Science and Surgical WorkflowsAdjusted Gross Profit – Bridge Q3 2020 – Q3 2021

66 22

-1,132

4,378

Q3 2020 Acute Care

Therapies

Life Science Surgical

Workflows

3,334

Q3 2021

MS

EK

60.7

(62.4)

44.3 41.7Adj GM, %

Q3 2021(Q3 2020)

52.9

October 20, 2021


Page 8

(57.4)(Q3 2019) (40.4) (43.3) (50.8)

3,171

Q3 2019

Gross Margin impact

Volume

Currency

Product mix

Factory absorption

(42.6) (39.0) (54.9)

Financial development

October 20, 2021


Page 9

Margin development-1.9 pp GP

-3.5 pp OPEX

-0.8 pp D&A

-0.8 pp Currency

Adj EBITA down vs Q3 2020 but up more than 70% vs Q3 2019Adjusted EBITA – Bridge Q3 2020 – Q3 2021

October 20, 2021

25.4% 18.4%

59 33 9 36 39

-1,044

1,160

2,028

Adj SellingQ3 2020 Adj Gross

profit

Adj Admin OtherAdj R&D D&A Q3 2021

MS

EK

-868


Page 10

677

Q3 2019

-64Currency impact, MSEK

October 20, 2021

Strong free cash flow and good control of working capitalContinued efficiency enhancements

Strong Free Cash Flow

110

90

0

100

120

140

130

Q4 2

020

Q1 2

018

Q2 2

020

Q1 2

021

Q4 2

017

Q2 2

018

Q3 2

018

Q1 2

019

Q2 2

019

Q3 2

019

Q4 2

019

Q1 2

020

Q3 2

020

Q2 2

021

Q3 2

021

Q4 2

018

Reduction

of -39 days

WC days well below 100

Working Capital Days LTM


Page 11

Working Capital, as defined on this page, is including accounts receivables, accounts payables and inventory - adjusted for currencyROIC: Trailing 12 month adjusted EBIT/Invested Capital. Invested Capital is equal to (Invested capital is defined as Equity + Net debt (excl. pension liabilities) and calculated as (Opening balance + Closing balance of Invested Capital)/2.

High Return on Invested Capital

Q4 2

019

Q1 2

020

7.5%

Q2 2

019

Q3 2

021

Q3 2

019

Q2 2

020

18.8%

Q4 2

020

Q3 2

020

Q1 2

021

Q2 2

021

Operating ROIC LTM

2.0

2.3

1.6

Q2 2

021

Q3 2

020

Q4 2

020

Q1 2

021

1.2 1

.4Q

3 2

021

Free Cash Flow, BSEK

October 20, 2021

Solid financial positionStrengthened even further

Improved net debt …


Page 12

… and leverage

3.4x

Q1 2

019

Q2 2

019

Q3 2

019

Q2 2

020

Q4 2

019

Q1 2

020

Q3 2

020

Q4 2

020

Q2 2

021

Q1 2

021

0.6x

Q3 2

021

Net debt/Adj EBITDA R12

(0.1x excluding

pension liabilities)

Q3 2

021

Q3 2

020

14.0

Q1 2

019

Q1 2

020

Q2 2

019

Q3 2

019

Q2 2

020

Q4 2

019

Q4 2

020

Q1 2

021

Q2 2

021

4.1

Net debt, BSEK

Summary

October 20, 2021


Page 13

• Strong organic order growth

• Good activity level and progress on strategy implementation

• EBITA margin adjusted for Covid-19 continues to improve

• Solid financial position

Summary Q3 2021

Key takeaways

October 20, 2021


Page 14

Q&A

October 20, 2021


Page 15

Thank you

October 20, 2021


Page 16

This document contains forward-looking information based on the current expectations of the Getinge’s management.

Although management deems that the expectations presented by such forward-looking information are reasonable, no

guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary

considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions

regarding business cycles, market and competition, changes in legal requirements and other political measures, and

fluctuations in exchange rates.

Forward looking information

October 20, 2021


Page 17

Documents

Presentation Q3 Report 2021 “Strong order growth and our